Get the Stockscreener App
73.00
0.98%
0.71
Tarsus Pharmaceuticals Inc stock is traded at $73.00, with a volume of 384.84K.
It is up +0.98% in the last 24 hours and down -6.69% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
See More
Previous Close:
$72.29
Open:
$72.585
24h Volume:
384.84K
Relative Volume:
0.39
Market Cap:
$3.42B
Revenue:
$535.08M
Net Income/Loss:
$-48.27M
P/E Ratio:
-64.40
EPS:
-1.1335
Net Cash Flow:
$-31.54M
1W Performance:
+1.08%
1M Performance:
-6.69%
6M Performance:
+1.67%
1Y Performance:
-2.60%
1-Day Range:
$72.45
$74.94
1-Week Range:
$70.03
$76.64
52-Week Range:
$53.89
$91.53
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
73.00 | 3.42B | 535.08M | -48.27M | -31.54M | -1.1335 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-26 | Resumed | Goldman | Buy |
| Sep-16-26 | Resumed | Barclays | Overweight |
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-20-25 | Initiated | Mizuho | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals (TARS) director adds 201 shares through RSU conversion - Stock Titan
Tarsus Pharmaceuticals (TARS) director sells shares under preset plan - Stock Titan
Nearly $1M Tarsus (NASDAQ: TARS) insider share sale planned by a company director - Stock Titan
Tarsus Pharmaceuticals (NASDAQ: TARS) Acquires Alkeus, Potential $350M Milestone Payments Included - Kalkine Media
Tarsus Pharmaceuticals Finalizes Acquisition of Alkeus Pharmaceuticals with $270M Cash and Stock Deal - Kalkine Media
Tarsus Pharmaceuticals COO Neervannan Seshadri Offloads 4,564 Shares at $85 Each (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals CEO Bobak Azamian Executes Open-Market Sale of 10,000 Shares at $90.27-$91.27 (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals CMO Executes Stock Sales Under Dual 10b5-1 Trading Plans - Kalkine Media
Tarsus (NASDAQ: TARS) CEO sells 10,000 shares under 10b5-1 plan - Stock Titan
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com - Investing.com Nigeria
Tarsus Pharmaceuticals gains analyst boost afte... - Pluang
TARS Maintains by Jefferies -- Price Target Raised to $105 - GuruFocus
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com - Investing.com Canada
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com - Investing.com India
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com - Investing.com UK
Tarsus Finalizes Alkeus Acquisition, Expanding Eyecare Pipeline - VisionMonday.com
Tarsus Finalizes Alkeus Acquisition, Expanding Eyecare Pipeline - visionmonday.com
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com - Investing.com South Africa
Officer at Tarsus (NASDAQ: TARS) lines up six-figure stock sale - Stock Titan
After recent sales, Tarsus (NASDAQ: TARS) officer's spouse plans another stock trade - Stock Titan
About $943K in stock set for sale at Tarsus (TARS) - Stock Titan
Planned Tarsus (TARS) officer sale covers 4,564 shares - Stock Titan
Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition - marketscreener.com
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com - Investing.com Nigeria
Tarsus Pharmaceuticals CEO Bobak R. Azamian Offloads 10,000 Shares at $80.06 Each (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD - investing.com
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD - Investing.com India
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care - manilatimes.net
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care - GlobeNewswire
A potentially blinding eye disease has no FDA-approved therapy. Tarsus bought a company developing one. - Stock Titan
Tarsus Pharmaceuticals (TARS) CEO sells 10,000 shares in plan trade - Stock Titan
Shareholder plans new stock sale at Tarsus (NASDAQ: TARS) - Stock Titan
Former Tarsus (NASDAQ: TARS) officer plans another stock sale - Stock Titan
Tarsus (NASDAQ: TARS) exec plans $431K sale after recent $340K stock cash-out - Stock Titan
Tarsus (NASDAQ: TARS) officer lines up another stock sale - Stock Titan
Tarsus to Participate in Upcoming Investor Conferences - manilatimes.net
Tarsus to Participate in Upcoming Investor Conferences - Yahoo Finance
Ex-officer lines up third multimillion sale in Tarsus (NASDAQ: TARS) stock - Stock Titan
Planned $340K insider stock sale at Tarsus (NASDAQ: TARS) from vested pay - Stock Titan
Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 5.75 Million in Common Stocks - Moomoo
After $3.8M sale, Tarsus (TARS) ex-officer plans more selling - Stock Titan
Tarsus (TARS) Technicals: Finishes 1.69% Up at $72.70 in the Latest Session; Next Test: Support at $69.06 and Resistance at $76.34 Frame the Range in Latest TradingVWAP Bounce - vinanet.vn
Tarsus (NASDAQ: TARS) ex-officer plans sale of 53K shares - Stock Titan
Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 3.82 Million in Common Stocks - Moomoo
TimesSquare Capital Management LLC Takes $23.25 Million Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales GuidanceAnd What's Next - Sahm
Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention? - Sahm
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales GuidanceAnd What's Next - simplywall.st
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tarsus Pharmaceuticals Inc Stock (TARS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WILLIAM J LINK | DIRECTOR |
Sep 15 '26 |
Proposed Sale |
78.38 |
12,500 |
979,745 |
0 |
| Lin Elizabeth Yeu | Chief Medical Officer |
Sep 04 '26 |
Sale |
87.50 |
10,773 |
942,635 |
2,547 |
| Lin Elizabeth Yeu | Chief Medical Officer |
Sep 04 '26 |
Sale |
87.50 |
3,180 |
278,250 |
1,590 |
| Neervannan Seshadri | Chief Operating Officer |
Sep 04 '26 |
Sale |
85.00 |
4,564 |
387,940 |
78,532 |
| BOBAK AZAMIAN | OFFICER |
Sep 04 '26 |
Proposed Sale |
90.56 |
10,000 |
905,587 |
0 |
| Lin Elizabeth Yeu | Member of immediate family of |
Sep 04 '26 |
Proposed Sale |
87.50 |
3,180 |
278,250 |
0 |
| Lin Elizabeth Yeu | Officer |
Sep 04 '26 |
Proposed Sale |
87.50 |
10,773 |
942,635 |
0 |
| Azamian Bobak R. | President/CEO and Board Chair |
Sep 04 '26 |
Sale |
90.56 |
10,000 |
905,600 |
827,991 |
| Neervannan Seshadri | Officer |
Sep 04 '26 |
Proposed Sale |
85.00 |
4,564 |
387,940 |
0 |
| BOBAK AZAMIAN | OFFICER |
Sep 02 '26 |
Proposed Sale |
80.06 |
10,000 |
800,569 |
0 |
2.16%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):